The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
This partnership has led to a 10% boost in delivery speed
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Subscribe To Our Newsletter & Stay Updated
